抄録
Objective The aim of this study was to evaluate the safety and efficacy of allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen (RIST) for interferon-α-refractory metastatic renal cell carcinoma (RCC). Patients and methods Of 26 patients referred to the National Cancer Center Hospital for possible RIST between June 2000 and April 2002, an HLA-identical relative was identified for 12 patients. Nine patients underwent RIST. The conditioning regimen consisted of fludarabine 180 mg/m 2 or cladribine 0.66 mg/kg, plus busulfan 8 mg/kg and rabbit antithymocyte globulin 5 mg/kg. Graft-vs-host disease (GVHD) prophylaxis was cyclosporine alone. Results All patients achieved engraftment without grade III to IV nonhematologic regimen-related toxicity. All patients achieved complete donor-type chimerism without donor lymphocyte infusion by day 60. Four patients developed acute GVHD, and four developed chronic GVHD. One patient (11%) achieved partial response. As of July 2003, six patients were alive at median follow-up of 681 days. The actuarial overall survival rate was 89% at 1 year and 74% at 2 years. The overall survival rate tended to be higher in the 12 patients with a matched donor than in the other 14 patients without a matched donor (p=0.088). Conclusion Our RIST procedure is feasible without severe toxicity. The efficacy of RIST for RCC should be confirmed in phase II/III clinical trials.
| 元の言語 | English |
|---|---|
| ページ（範囲） | 599-606 |
| ページ数 | 8 |
| ジャーナル | Experimental Hematology |
| 巻 | 32 |
| 発行部数 | 7 |
| DOI | |
| 出版物ステータス | Published - 2004 7 |
| 外部発表 | Yes |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Cell Biology
- Genetics
- Hematology
- Oncology
- Transplantation
これを引用
Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma : Single institution experience with a minimum 1-year follow-up. / Nakagawa, Tohru; Kami, Masahiro; Hori, Akiko; Kim, Sung Won; Murashige, Naoko; Hamaki, Tamae; Kishi, Yukiko; Fujimoto, Hiroyuki; Matsuoka, Naoki; Okajima, Eijiro; Komiyama, Motokiyo; Tobisu, Ken Ichi; Wakayama, Toshio; Uike, Naokuni; Tajima, Kinuko; Makimoto, Atsushi; Mori, Shinichiro; Tanosaki, Ryuji; Takaue, Yoichi; Kakizoe, Tadao.
：: Experimental Hematology, 巻 32, 番号 7, 07.2004, p. 599-606.研究成果: Article
}
TY - JOUR
T1 - Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma
T2 - Single institution experience with a minimum 1-year follow-up
AU - Nakagawa, Tohru
AU - Kami, Masahiro
AU - Hori, Akiko
AU - Kim, Sung Won
AU - Murashige, Naoko
AU - Hamaki, Tamae
AU - Kishi, Yukiko
AU - Fujimoto, Hiroyuki
AU - Matsuoka, Naoki
AU - Okajima, Eijiro
AU - Komiyama, Motokiyo
AU - Tobisu, Ken Ichi
AU - Wakayama, Toshio
AU - Uike, Naokuni
AU - Tajima, Kinuko
AU - Makimoto, Atsushi
AU - Mori, Shinichiro
AU - Tanosaki, Ryuji
AU - Takaue, Yoichi
AU - Kakizoe, Tadao
PY - 2004/7
Y1 - 2004/7
N2 - Objective The aim of this study was to evaluate the safety and efficacy of allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen (RIST) for interferon-α-refractory metastatic renal cell carcinoma (RCC). Patients and methods Of 26 patients referred to the National Cancer Center Hospital for possible RIST between June 2000 and April 2002, an HLA-identical relative was identified for 12 patients. Nine patients underwent RIST. The conditioning regimen consisted of fludarabine 180 mg/m 2 or cladribine 0.66 mg/kg, plus busulfan 8 mg/kg and rabbit antithymocyte globulin 5 mg/kg. Graft-vs-host disease (GVHD) prophylaxis was cyclosporine alone. Results All patients achieved engraftment without grade III to IV nonhematologic regimen-related toxicity. All patients achieved complete donor-type chimerism without donor lymphocyte infusion by day 60. Four patients developed acute GVHD, and four developed chronic GVHD. One patient (11%) achieved partial response. As of July 2003, six patients were alive at median follow-up of 681 days. The actuarial overall survival rate was 89% at 1 year and 74% at 2 years. The overall survival rate tended to be higher in the 12 patients with a matched donor than in the other 14 patients without a matched donor (p=0.088). Conclusion Our RIST procedure is feasible without severe toxicity. The efficacy of RIST for RCC should be confirmed in phase II/III clinical trials.
AB - Objective The aim of this study was to evaluate the safety and efficacy of allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen (RIST) for interferon-α-refractory metastatic renal cell carcinoma (RCC). Patients and methods Of 26 patients referred to the National Cancer Center Hospital for possible RIST between June 2000 and April 2002, an HLA-identical relative was identified for 12 patients. Nine patients underwent RIST. The conditioning regimen consisted of fludarabine 180 mg/m 2 or cladribine 0.66 mg/kg, plus busulfan 8 mg/kg and rabbit antithymocyte globulin 5 mg/kg. Graft-vs-host disease (GVHD) prophylaxis was cyclosporine alone. Results All patients achieved engraftment without grade III to IV nonhematologic regimen-related toxicity. All patients achieved complete donor-type chimerism without donor lymphocyte infusion by day 60. Four patients developed acute GVHD, and four developed chronic GVHD. One patient (11%) achieved partial response. As of July 2003, six patients were alive at median follow-up of 681 days. The actuarial overall survival rate was 89% at 1 year and 74% at 2 years. The overall survival rate tended to be higher in the 12 patients with a matched donor than in the other 14 patients without a matched donor (p=0.088). Conclusion Our RIST procedure is feasible without severe toxicity. The efficacy of RIST for RCC should be confirmed in phase II/III clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=3042790638&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3042790638&partnerID=8YFLogxK
U2 - 10.1016/j.exphem.2004.04.006
DO - 10.1016/j.exphem.2004.04.006
M3 - Article
C2 - 15246155
AN - SCOPUS:3042790638
VL - 32
SP - 599
EP - 606
JO - Experimental Hematology
JF - Experimental Hematology
SN - 0301-472X
IS - 7
ER -